Table 5.
Prevalence of abnormal LFTs in different conditions identified in the BALLETS study
| Cause | Percentage prevalence (%) |
|---|---|
| NAFLD | 26.4 |
| At-risk alcohol intake | 25.3 |
| Non-fatty liver | 14.0 |
| Fatty liver | 11.3 |
| Primary biliary cirrhosis | 0.81 |
| Hepatitis B | 0.72 |
| Haemochromatosis | 0.90 |
| Other (cancer, drug, abscess) | 0.36 |
| Hepatitis C | 0.17 |
| Primary sclerosing cholangitis | 0.17 |
| Alpha-1-antitrypsin Deficiency | 0.17 |
| Unexplained group | 45.1 |
* ALFIE study not all patients received both an ALT and an AST. It should also be noted that, as the BALLETS study chose patients with an abnormal LFT from the native population, this selection bias will overestimate the sensitivity and underestimate the specificity